• Brenntag entered a strategic partnership with phosphate maker Budenheim to expand supply of high-purity, GMP-grade biopharma phosphates.
• Budenheim becomes the first co-brand partner for Brenntag’s global BYPHAR biopharma brand.
• Budenheim’s biopharma phosphate portfolio will be sold globally under BYPHAR in packs of 15 kg or less, targeting early-stage to commercial needs.
• Budenheim’s PharSQ Pure line in 25 kg or larger packs will be distributed by Brenntag across Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brenntag SE published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.